{"id":"8e202aa5-8b90-52ad-a9a8-3f5fafa3635e","stable_key":"773f772e-bf8e-5e52-a2a2-6dd694d67f5d:bromelain-human-cytokine-shift","predicate":"changes","statement":"A single-dose placebo-controlled crossover trial found a significant shift in the IFN-gamma circadian profile after 3000 FIP units of oral bromelain.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"a38a04e8-d501-5567-891d-67bae9ebb02b","mechanism_event_label":"A single-dose placebo-controlled crossover trial found a significant shift in the IFN-gamma circadian profile after 3000 FIP units of oral bromelain.","subject":{"id":"6a3990e6-85af-58c7-8087-8a251db842fa","slug":"bromelain","display_name":"Bromelain","entity_type_key":"peptide"},"object":{"id":"facb826e-552e-50e1-be35-a61e4686c874","slug":"human-stimulated-whole-blood-ifng-circadian-profile","display_name":"IFN-gamma circadian response in stimulated human whole blood","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"a38a04e8-d501-5567-891d-67bae9ebb02b","stable_key":"773f772e-bf8e-5e52-a2a2-6dd694d67f5d:bromelain-human-cytokine-shift-event","event_type":"observed_relationship","label":"A single-dose placebo-controlled crossover trial found a significant shift in the IFN-gamma circadian profile after 3000 FIP units of oral bromelain.","description":"A single-dose placebo-controlled crossover trial found a significant shift in the IFN-gamma circadian profile after 3000 FIP units of oral bromelain.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6a3990e6-85af-58c7-8087-8a251db842fa","slug":"bromelain","display_name":"Bromelain","entity_type_key":"peptide"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"facb826e-552e-50e1-be35-a61e4686c874","slug":"human-stimulated-whole-blood-ifng-circadian-profile","display_name":"IFN-gamma circadian response in stimulated human whole blood","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"8b483912-bed0-50b7-a9b3-ec45ce5156da","slug":"interferon-gamma","display_name":"Interferon gamma","entity_type_key":"protein"},"role":"context_participant","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"dose","value_text":"Single oral dose; high dose 3000 FIP units","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"duration","value_text":"Circadian sampling after one dose","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_scope","value_text":"literature_reviewed; model-specific source-derived curation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Healthy human volunteers in a three-way crossover trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"The clinical relevance and effect in a diseased immune system were not established; IL-5 and IL-10 findings were trends.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Bromelain chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings.","comparator":null,"unit":null,"notes":"","entity":{"slug":"bromelain","display_name":"Bromelain","entity_type_key":"peptide"}},{"dimension":"organism","value_text":"Healthy human volunteers in a three-way crossover trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"A single-dose placebo-controlled crossover trial found a significant shift in the IFN-gamma circadian profile after 3000 FIP units of oral bromelain.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Placebo-controlled randomized clinical trial on the immunomodulating activities of low- and high-dose bromelain after oral administration - new evidence on the antiinflammatory mode of action of bromelain. (2013). https://pubmed.ncbi.nlm.nih.gov/22517542/ DOI: 10.1002/ptr.4678","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Ex-vivo stimulated whole-blood cytokine profiles","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"73959f4a-4215-504f-bab7-fa62e99b4759","evidence_kind":"source_excerpt","locator":"Lines 99-108","start_line":99,"end_line":108,"excerpt":"## bromelain-human-cytokine-shift\nA single-dose placebo-controlled crossover trial found a significant shift in the IFN-gamma circadian profile after 3000 FIP units of oral bromelain.\nModel/species: Healthy human volunteers in a three-way crossover trial\nTissue/system: Ex-vivo stimulated whole-blood cytokine profiles\nExposure: Single oral dose; high dose 3000 FIP units\nRoute: Oral\nDuration: Circadian sampling after one dose\nLimits: The clinical relevance and effect in a diseased immune system were not established; IL-5 and IL-10 findings were trends.\nPrimary reference: Placebo-controlled randomized clinical trial on the immunomodulating activities of low- and high-dose bromelain after oral administration - new evidence on the antiinflammatory mode of action of bromelain. (2013). https://pubmed.ncbi.nlm.nih.gov/22517542/ DOI: 10.1002/ptr.4678\nAccess: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","model_system":"Healthy human volunteers in a three-way crossover trial","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact original curation span with primary citation; not a publisher quotation.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"9d363b4e-f438-5664-9d74-99c2e359391d","stable_key":"import-773f772e-bf8e-5e52-a2a2-6dd694d67f5d","title":"Bromelain: mechanism of action and interactions (2026-09-20)","document_type":"imported_text","citation_label":"Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text.","file_path":"","sha256":"b328dbb8082bea612bb2c40d6ff41fa670f6e62f714bd014c90627fcab86e95b","revision_id":"1c10d22e-ecdf-56ef-b820-bb21182a9577","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}